演題詳細

ポスター / Poster

ポスター 3 (Poster 3) :鉄キレート療法 (Iron Chelate Therapy)

print

日程
2013年10月11日(金)
時間
16:50 - 17:50
会場
ポスター会場 / Poster (ロイトン札幌 3F ロイトンホールABCD)
座長・司会
藤島 眞澄 (Masumi Fujishima):1
1:秋田大学医学部 血液・腎臓・膠原病内科学
 
前へ戻る

Efficacy of early intervention of deferasirox in patinets with transfusional iron overload

演題番号 : PS-1-16

芦田 隆司 (Takashi Ashida):1,2、丸瀬 ちほ (Chiho Maruse):1、福島 靖幸 (Yasuyuki Fukushima):1、川野 亜美 (Ami Kawano):1、山田 枝里佳 (Erika Yamada):1、井手 大輔 (Daisuke Ide):1、菅野 知恵美 (Chiemi Sugano):1、加藤 祐子 (Yuko Kato):1、椿本 祐子 (Yuko Tsubakimoto):1、伊藤 志保 (Shiho Ito):1、峯 佳子 (Yoshiko Mine):1、藤田 往子 (Michiko Fujita):1、金光 靖 (Yasushi Kanemitsu):1、森嶋 祥之 (Yoshiyuki Morishima):1、森田 泰慶 (Yasuyoshi Morita):2、田中 宏和 (Hirokazu Tanaka):2、嶋田 高広 (Takahiro Shimada):2、宮武 淳一 (Junichi Miyatake):2、辰巳 陽一 (Yoichi Tatsumi):2、松村 到 (Itaru Matsumura):1,2

1:Center for Transfusion Medicine and Cell Therapy, Kinki University, Japan、2:Division of Hematology and Rheumatology, Kinki University, Osakasayama, Japan

 

[Introduction] Many patients with bone marrow failure syndrome need frequent red blood cell (RBC) transfusions. Also, most of them develop organ dysfunction due to transfusional iron overloads. Recently, a novel iron chelator, deferasirox, has been developed, and efficacy of deferasirox was reported. The National Research Group on Idiopathic Bone Marrow Failure Syndromes in Japan drew up Japanese guidelines for the treatment of transfusion-induced iron overload. In this guideline, confirmation of both total RBC >40 units and serum ferritin >1,000 ng/ml is recommended to initiate iron chelating therapy. We studied efficacy of early intervention of deferasirox in patients with transfusional iron overload retrospectively. [Patients and Methods] We review a total of 50 patients treated deferasirox. We studied a correlation between serum ferritin levels at initiating of deferasirox and efficacy of iron chelation therapy.[Results] The diagnoses were 10 AA, 2 PRCA, 27 MDS, 4 AML, 1 CML, 1 malignant lymphoma, 1 MM, 1 PV and 3 MF. Median serum ferritin level at initiating of deferasirox was 1,243 ng/ml (range 260 - 10,366 ng/ml). Of 44 patients who did not receive stem cell transplantation, 28 patients (63.6%) discontinued deferasirox due to adverse events, hematologic responses, deterioration of primary diseases and economic reason. [Conclusion] Deferasirox is effective in patients with transfusional iron overload. However, deferasirox has a lot of adverse events. It may be necessary to examine about initiating doses and timing of deferasirox.

前へ戻る